Adhesive drug delivery composition
AssigneeWest Pharmaceutical Services Drug Delivery and Clinical Research Limited
InventorsLisbeth Illum, Paul Williams, Antony James Caston
Life of this patent
Estimating the term…
Abstract
Adhesive material from the fimbriae (esp. Type 1) of bacteria or synthetic analogues or fragments thereof is combined with a drug to provide for attachment to the gut of a mammal, thereby prolonging the transit time of the drug through the gut. The 28 kDa polypeptide from E. coli Type 1 fimbriae is the preferred adhesive material (“adhesin”). The drug is presented in a carrier such as albumin, a polylactide/glycolide copolymer or alginate microcapsules. The adhesin may be incorporated in the carrier during preparation thereof, adsorbed onto the carrier after preparation, or covalently linked thereto, for example with carbodiimide.
Claims26
A drug delivery composition comprising
- particles comprising a drug and a bacterial bioadhesive material binding via a sugar residue, lectin-mediated process to the small intestine of a mammal,
- wherein the bioadhesive material is incorporated on the surface of the particles either by coating or covalent binding.
A drug delivery composition for sustained release of a drug in the gastrointestinal tract comprising:
- liposomes or an emulsion having incorporated therein;
- at least one drug, and
- a bacterial bioadhesive material binding to the small intestine of a mammal via a sugar residue, lectin-mediated process, wherein the bioadhesive material is linked to a lipid entrapped in the liposomes or emulsion, and wherein the liposomes or emulsion are bound to the small intestine by the bioadhesive material to permit sustained release of the drug to the gastrointestinal tract of a mammal.
A method of treating a mammal comprising administering orally to the mammal a therapeutically effective amount of a drug delivery composition comprising polymeric particles, having incorporated therein a drug and having coupled to the surface a bacterial bioadhesive material binding to the small intestine of a mammal via a sugar residue, lectin-mediated process for a period of time permitting controlled release of the drug to the gastrointestinal tract of the mammal.
A method of treating a mammal comprising administering orally to the mammal a therapeutically effective amount of a drug delivery composition comprising
- liposomes or an emulsion having incorporated therein at least one drug, and
- a bacterial bioadhesive material binding via a sugar residue lectin-mediated process to the small intestine, which is linked to a lipid entrapped in the liposomes or emulsion, and which adheres to the small intestine for a period of time permitting controlled release of the drug.
Dependencies are inferred from the claim text.